RCMNY
EIDX

Rubric Capital Management (New York)’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Rubric Capital Management (New York)’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-28,579
Closed -$1.64M – 66
2019
Q4 		$1.64M Buy
+28,579
New +$1.42M 0.19% 45

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Rubric Capital Management (New York)'s EIDX Position: Q1 2020 in Review

Rubric Capital Management (New York) sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2020, closing a stake of 28,579 shares — an estimated $1.64M sold.

Rubric Capital Management (New York) first reported a position in EIDX in Q4 2019 and held it in 1 quarter. The position peaked at $1.64M in Q4 2019. 89 funds tracked by Wall St. Rank hold EIDX as of Q1 2020.

  • Rubric Capital Management (New York) reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 28,579 Eidos Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $1.64M.
  • Rubric Capital Management (New York) first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Rubric Capital Management (New York)'s Eidos Therapeutics, Inc. Common Stock position peaked at $1.64M in Q4 2019.
  • 89 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2020, filed 14 May 2020.